Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug manufacturing

EMA recommends sartan manufacturers review processes to avoid contamination

The European Medicines Agency (EMA) has recommended that manufacturers making sartan blood pressure medicines review their processes after impurities were found in a small number of products.

The impurities, N-nitrosodimethylamine (NDMA) and N‑nitrosodiethylamine (NDEA), are classified as possible human carcinogens and, under the recommendations, companies would have to adhere to strict limits on the levels of the impurities that can be found in sartan medicines for two years.

Products found to contain either NDMA or NDEA above the set limits would not be allowed in the EU.

This comes after the Medicines and Healthcare products Regulatory Agency issued a further recall of irbesartan-containing medication from UK pharmacies, due to NDMA and NDEA contamination, on 28 January 2019.

Several valsartan products were recalled in 2018.

Irbesartan is one of five active substances subject to the new limits, in addition to candesartan, losartan, olmesartan and valsartan. The set limits vary for each active substance.

The EMA said that these impurities can form during the production of sartans containing a tetrazole ring under certain conditions and when certain solvents, reagents, and other raw materials are used.

It added that impurities could also be present “because manufacturers had inadvertently used contaminated equipment or reagents in the manufacturing process”.

After the two year transition period, in which manufacturers are expected to adjust their processes to limit contamination, companies will have to demonstrate that their sartan products contain none of these impurities before they can be used in the EU.

The EMA’s recommendations for NDMA and NDEA are now awaiting a legally binding decision from the European Commission.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206101

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.